"It has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate nasal spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a competitive generic therapy (CGT) designation," the company said in a filing to BSE.Cipla gets final nod from USFDA for migraine treatment nasal spray
"It has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate nasal spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a competitive generic therapy (CGT) designation," the company said in a filing to BSE.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
"Paytm is now empowering feature phone users to recharge for their Vodafone Idea numbers with just a valid UPI ID. Along with the tele...
No comments:
Post a Comment